solid tumors tagged posts

Nanotechnology used to Destroy and Prevent Relapse of Solid Tumor Cancers

 B7 co-stimulation enhances the anti-PD1-based immunosuppression reversal.

As people across the globe look forward to longer life expectancies, malignant cancers continue to pose threats to human health. The exploration and development of immunotherapy aims to seek new breakthroughs for the treatment of solid tumours.

The successful establishment of anti-tumour immunity requires the activation, expansion and differentiation of antigen-specific lymphocytes. This process largely depends on specific interactions between various T cells and antigen-presenting cells (APCs) in the body. However, existing tumour vaccines, such as neoantigen vaccines and various vector vaccines, all rely on random interactions with APCs in the body...

Read More

Fighting Cancer with Immunotherapy: Signaling molecule causes regression of blood vessels

A microscopic image of tumor tissue under the influence of TNF (left) and IFN- ? (right). Red blood cells are pictured in a magenta color. TNF bursts the blood vessels and releases large amounts of blood cells, whereas IFN-? lets vessels retreat. Credit: Christian Friese / MDC

A microscopic image of tumor tissue under the influence of TNF (left) and IFN- ? (right). Red blood cells are pictured in a magenta color. TNF bursts the blood vessels and releases large amounts of blood cells, whereas IFN-? lets vessels retreat. Credit: Christian Friese / MDC

Immunotherapy with T-cells offers great hope to people suffering from cancer. Some initial successes have already been made in treating blood cancer, but treating solid tumors remains a major challenge. The signaling molecule interferon gamma, produced by T-cells, plays a key role in the therapy. It cuts off the blood supply to tumors. The immune system is the body’s most powerful weapon against diseases...

Read More

Gene Therapy: T cells target Mutations to fight Solid Tumors:

The T cell receptor on T cells might recognize antigens derived from mutated proteins in cancer cells. Once a foreign "non-self" antigen is detected, the T cell will kill the cancer cell. Credit: Matthias Leisegang.

The T cell receptor on T cells might recognize antigens derived from mutated proteins in cancer cells. Once a foreign “non-self” antigen is detected, the T cell will kill the cancer cell. Credit: Matthias Leisegang.

T cell therapies with less side effects. An international team has successfully modified immune cells to recognize and specifically target tumor cells in mice. Cancer treatments based on the findings would likely have fewer side effects than standard therapies. Although T cells migrate into tumors and recognize antigens, the defense mechanism seems to fail during the formation of tumors. T cells in the tumors are usually inactive and therapeutically almost useless...

Read More